- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07690241
Health Informatics Education Effectiveness in Nepal (HI-EDU)
7 luglio 2026 aggiornato da: Dip Bahadur Singh, Axon Infotech Research Academy Pvt. Ltd.
Assessing the Comparative Effectiveness of Health Informatics Education: Knowledge Retention and Technological Awareness in Health Science Students
This study evaluates the effectiveness of a blended Health Informatics (HI) course (HI471) on knowledge retention and technology awareness among health science students in Nepal.
Bachelor of Public Health (BPH) students (intervention group, n=17) received a 14-week HI471 course combining online, virtual, and in-person practical sessions.
A control group of Bachelor of Pharmacy (B.Pharm) students (n=17) continued their standard curriculum without dedicated HI instruction.
Both groups completed a validated 44-item knowledge assessment and an 11-item technology awareness survey at baseline (Week 1) and post-intervention (Week 15).
The primary outcome was the between-group difference in knowledge gain scores.
Results showed that BPH students significantly improved their total knowledge scores (median +31.5 points, r=0.879), while the B.Pharm control group showed no significant change.
BPH students achieved 100% awareness of 9 out of 11 digital health tools at post-test.
This study provides strong evidence that the HI471 blended course is highly effective in building informatics competencies in a low- and middle-income country (LMIC) academic setting.
The study was retrospectively registered.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This controlled pre-test/post-test quasi-experimental study with a non-equivalent control group evaluated the effectiveness of the Health Informatics-471 (HI471) blended course at Madan Bhandari Academy of Health Sciences (MBAHS) in Nepal.
The intervention group (G1) consisted of all 17 Bachelor of Public Health (BPH) students enrolled in the 7th semester, who received the HI471 course.
The control group (G2) consisted of 17 Bachelor of Pharmacy (B.Pharm) 7th-semester students, randomly sampled from 29 eligible students, who received no dedicated HI instruction.
The HI471 course integrated three blended modalities over 14 weeks: (i) online asynchronous LMS instruction (pre-recorded lectures, readings, quizzes), (ii) live synchronous Google Meet sessions, and (iii) in-person practical laboratory sessions covering EHR platforms, DHIS2, SPSS/R, and telemedicine interfaces.
A validated 44-item Health Informatics Knowledge Assessment Tool (with weighted partial-credit scoring, maximum 100 points) and an 11-item binary technology awareness instrument were administered at T1 (Week 1, baseline) and T2 (Week 15, post-intervention).
The primary outcome was the between-group difference in total knowledge gain scores (Δ = T2 - T1), analyzed using non-parametric statistics (Mann-Whitney U, Wilcoxon signed-rank, Friedman, McNemar) with bootstrap effect sizes.
The study demonstrated large, significant knowledge gains in the intervention group (median +31.5 points, r=0.824, p<0.001) compared to the control group, with robust findings across three pre-specified sensitivity analyses.
The intervention group achieved near-complete technology awareness (100% on 9 out of 11 tools).
This research addresses the evidence gap for controlled educational evaluations in low- and middle-income country (LMIC) academic settings.
The study protocol was approved by the MBAHS Institutional Review Committee (IRC-134-082-083), and all participants provided written informed consent.
The study was conducted in compliance with the Declaration of Helsinki (revised 2013).
The study was registered retrospectively.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
34
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Bagmati
-
Hetauda, Bagmati, Nepal, 31206
- Madan Bhandari Academy of Health Sciences
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Sì
Descrizione
Inclusion Criteria:
- Active enrollment in the 7th semester of the Bachelor of Public Health (BPH) program (intervention group) or the Bachelor of Pharmacy (B.Pharm) program (control group) at Madan Bhandari Academy of Health Sciences (MBAHS).
- Voluntary written informed consent obtained prior to any study procedure.
- Completion of both T1 (Week 1, baseline) and T2 (Week 15, post-intervention) assessments.
Exclusion Criteria:
- Withdrawal from the study before completion of all study procedures.
- Incomplete paired data (missing T1 or T2 assessment).
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: BPH Intervention Group
Bachelor of Public Health (BPH) 7th-semester students (n=17) who received the 14-week Health Informatics-471 (HI471) blended course, consisting of online asynchronous LMS instruction, live synchronous Google Meet sessions, and in-person practical laboratory work covering seven HI content domains.
|
A 14-week blended educational course combining: (i) online asynchronous LMS instruction (pre-recorded lectures, readings, quizzes); (ii) live synchronous Google Meet sessions (2 hours, 3 days per week); and (iii) in-person practical laboratory sessions (4 hours per week) covering Electronic Health Records (EHR), DHIS2, SPSS/R, and telemedicine interfaces.
No drug, device, biological product, or surgical procedure was involved.
This is a purely educational/behavioral intervention delivered in an academic setting.
|
|
Nessun intervento: B.Pharm Control Group
Bachelor of Pharmacy (B.Pharm) 7th-semester students (n=17) who continued their standard curriculum without any dedicated Health Informatics instruction.
This group served as the non-equivalent control group.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Total Health Informatics Knowledge Score
Lasso di tempo: Baseline (Week 1) to post-intervention (Week 15)
|
Measured using the Health Informatics Knowledge Assessment Tool (HIKAT) - a validated 44-item multiple-select instrument with weighted partial-credit scoring.
Scores range from 0 to 100 points, where higher scores indicate better health informatics knowledge.
Administered to both groups at T1 (Week 1, pre-test) and T2 (Week 15, post-test).
The primary causal contrast is the between-group difference in gain scores (Δ = T2 - T1), analyzed using Mann-Whitney U test with bootstrapped effect sizes.
|
Baseline (Week 1) to post-intervention (Week 15)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Domain-Specific Knowledge Gains Across Six HI Content Areas
Lasso di tempo: Baseline (Week 1) to post-intervention (Week 15)
|
Change in knowledge scores across six domain areas assessed using the Health Informatics Knowledge Assessment Tool (HIKAT): D1 General HI/Introduction to IT, D2 Operating Systems & Software, D3 Public Health & IT, D4 Database Management, D5+6 Data Analysis & Coding, and D7 Telemedicine.
Each domain score is expressed as a percentage of the domain maximum (minimum: 0%, maximum: 100%), where higher scores indicate greater domain-specific health informatics knowledge.
Domain gains are analyzed using Friedman test with Kendall W and Holm-corrected post-hoc Wilcoxon signed-rank tests within the intervention group.
|
Baseline (Week 1) to post-intervention (Week 15)
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Technological Awareness Across Digital Health Tools
Lasso di tempo: Baseline (Week 1) to post-intervention (Week 15)
|
Change in binary (Yes/No) awareness of 11 digital health tools: EHR, Telemedicine, HMIS, Public Health Informatics, GIS, HIMS, DBMS, Python, Programming Language, Telehealth Platforms, and Remote Patient Monitoring.
|
Baseline (Week 1) to post-intervention (Week 15)
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Investigatori
- Investigatore principale: Dip Bahadur Singh, Axon Infotech Research Academy
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
15 aprile 2026
Completamento primario (Effettivo)
20 giugno 2026
Completamento dello studio (Effettivo)
30 giugno 2026
Date di iscrizione allo studio
Primo inviato
2 luglio 2026
Primo inviato che soddisfa i criteri di controllo qualità
7 luglio 2026
Primo Inserito (Effettivo)
8 luglio 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
8 luglio 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
7 luglio 2026
Ultimo verificato
1 luglio 2026
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- HI471-MBAHS-2026
- IRC-134-082-083 (Identificatore di registro: Madan Bhandari Academy of Health Sciences IRC)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Individual participant data (IPD) will not be shared because participants did not provide consent for their individual-level data to be shared with external researchers.
Additionally, the small sample size (n=34) increases the risk of participant re-identification, even with de-identification.
All aggregated, anonymized summary data are presented in the published manuscript and supplementary materials
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .